Literature DB >> 15721757

Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?

Stephen J Kish1, Yoshiaki Furukawa, Li-Jan Chang, Junchao Tong, Nathalie Ginovart, Alan Wilson, Sylvain Houle, Jeffrey H Meyer.   

Abstract

INTRODUCTION: The primary approach in assessing the status of brain serotonin neurons in human conditions such as major depression and exposure to the illicit drug ecstasy has been the use of neuroimaging procedures involving radiotracers that bind to the serotonin transporter (SERT). However, there has been no consistency in the selection of a "SERT-free" reference region for the estimation of free and nonspecific binding, as occipital cortex, cerebellum and white matter have all been employed. OBJECTIVE AND METHODS: To identify areas of human brain that might have very low SERT levels, we measured, by a semiquantitative Western blotting procedure, SERT protein immunoreactivity throughout the postmortem brain of seven normal adult subjects.
RESULTS: Serotonin transporter could be quantitated in all examined brain areas. However, the SERT concentration in cerebellar cortex and white matter were only at trace values, being approximately 20% of average cerebral cortex and 5% of average striatum values.
CONCLUSION: Although none of the examined brain areas are completely free of SERT, human cerebellar cortex has low SERT binding as compared to other examined brain regions, with the exception of white matter. Since the cerebellar cortical SERT binding is not zero, this region will not be a suitable reference region for SERT radioligands with very low free and nonspecific binding. For SERT radioligands with reasonably high free and nonspecific binding, the cerebellar cortex should be a useful reference region, provided other necessary radioligand assumptions are met.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721757     DOI: 10.1016/j.nucmedbio.2004.10.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  57 in total

1.  A dose-finding study of duloxetine based on serotonin transporter occupancy.

Authors:  Akihiro Takano; Kazutoshi Suzuki; Jun Kosaka; Miho Ota; Shoko Nozaki; Yoko Ikoma; Shuji Tanada; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2006-02-28       Impact factor: 4.530

2.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 3.  How the cerebral serotonin homeostasis predicts environmental changes: a model to explain seasonal changes of brain 5-HTT as intermediate phenotype of the 5-HTTLPR.

Authors:  Jan Kalbitzer; Urs Kalbitzer; Gitte Moos Knudsen; Paul Cumming; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

4.  Cerebellar heterogeneity and its impact on PET data quantification of 5-HT receptor radioligands.

Authors:  Melanie Ganz; Ling Feng; Hanne Demant Hansen; Vincent Beliveau; Claus Svarer; Gitte M Knudsen; Douglas N Greve
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-11       Impact factor: 6.200

5.  The 5-HTTLPR Polymorphism Affects Network-Based Functional Connectivity in the Visual-Limbic System in Healthy Adults.

Authors:  Hengyi Cao; Anais Harneit; Henrik Walter; Susanne Erk; Urs Braun; Carolin Moessnang; Lena S Geiger; Zhenxiang Zang; Sebastian Mohnke; Andreas Heinz; Nina Romanczuk-Seiferth; Thomas Mühleisen; Manuel Mattheisen; Stephanie H Witt; Sven Cichon; Markus M Nöthen; Marcella Rietschel; Andreas Meyer-Lindenberg; Heike Tost
Journal:  Neuropsychopharmacology       Date:  2017-06-07       Impact factor: 7.853

6.  Serotonin transporter protein in autopsied brain of chronic users of cocaine.

Authors:  Junchao Tong; Jeffrey H Meyer; Isabelle Boileau; Lee-Cyn Ang; Paul J Fletcher; Yoshiaki Furukawa; Stephen J Kish
Journal:  Psychopharmacology (Berl)       Date:  2020-06-03       Impact factor: 4.530

Review 7.  Consensus paper: pathological role of the cerebellum in autism.

Authors:  S Hossein Fatemi; Kimberly A Aldinger; Paul Ashwood; Margaret L Bauman; Charles D Blaha; Gene J Blatt; Abha Chauhan; Ved Chauhan; Stephen R Dager; Price E Dickson; Annette M Estes; Dan Goldowitz; Detlef H Heck; Thomas L Kemper; Bryan H King; Loren A Martin; Kathleen J Millen; Guy Mittleman; Matthew W Mosconi; Antonio M Persico; John A Sweeney; Sara J Webb; John P Welsh
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

8.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Authors:  Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau
Journal:  Brain       Date:  2010-05-17       Impact factor: 13.501

9.  Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.

Authors:  Henricus G Ruhé; Jan Booij; Johannes B Reitsma; Aart H Schene
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

10.  The SPECT tracer [123I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men.

Authors:  Elsmarieke van de Giessen; Jan Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.